REG - Prudential PLC - Director/PDMR Shareholding

UBS Group AG has crossed the 5% voting rights threshold in Prudential Public Limited Company (PUK), according to a recent SEC filing. The bank now holds 5.01% of voting rights through shares and 0.11% through financial instruments, totaling 5.12% as of September 11, 2026.

Prudential Public reported a 13% increase in new-business profit for H1, with bancassurance contributing 42%. Agency profit rose 5%, and health profit grew 15%. China faced regulatory challenges, while Malaysia and Hong Kong showed strong growth. The company is investing in India and reaffirmed its 2026 and 2027 targets. Prudential's shareholder capital ratio is 268%.

India’s CCI cleared Prudential Corporation Holdings’ plan to buy a 75% stake in Bharti Life Insurance Company Ltd. The deal follows Prudential plc’s May announcement to pay Rs 3,500 crore (about $389m) for the majority stake. Prudential said it will adjust its existing ICICI Prudential holdings to meet rules and may seek distribution deals with Bharti Airtel and 360 ONE.

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.

Pinterest (PINS) appointed Amazon's James Dibbo as its new CFO. The company's stock has shown mixed performance, with a recent 7-day return of 7.52% but a 1-year return of -36.11%. Analysts have varying views on its valuation, with some seeing it as undervalued at $20.31 per share compared to a fair value estimate of $29.05, while others note its high P/E ratio of 46.2x.

Shanghai Allist Pharmaceuticals (SS:688578) shares dropped 20% after its U.S. partner ArriVent Biopharma (NASDAQ:AVBP) reported that a late-stage trial of lung cancer drug firmonertinib failed to meet its primary endpoint. The drug did not show a statistically significant improvement in progression-free survival for patients with non-small cell lung cancer.